Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Partner Janet Xiao offers optimism for cross-border deals in 2018 in the BioWorld article “‘Spirit’ of JPM lives on as other meetings muscle in on biopharma playground.”

‘Spirit’ of JPM lives on as other meetings muscle in on biopharma playground

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Partner Janet Xiao offers optimism for cross-border deals in 2018 in the BioWorld article “‘Spirit’ of JPM lives on as other meetings muscle in on biopharma playground.”“Biopharma is definitely the forerunner in terms of cross-border dealmaking,” she said, serving as a moderator at the Chinese American Biopharmaceutical Society (CABS) Investor Forum. Last year set a record for U.S.-China cross-border transactions in biopharma, she said, with assets in oncology and I-O, cell therapy and cardiovascular disease at the top of their prospect list, along with drug and device treatments for diabetes.Ms. Xiao continued to say that investors in China have grown more sophisticated about evaluating technologies that fill gaps in their internal development, “so the deals they're looking for have become more tailored to their specific needs.”Read the <a href="http://www.bioworld.com/content/spirit-jpm-lives-other-meetings-muscle-biopharma-playground-1" target="_blank">full article</a>.

‘Spirit’ of JPM lives on as other meetings muscle in on biopharma playground